Serial interferon-γ release assays for screening andmonitoring of tuberculosis infection during treatment with biologic agents

Clinical Rheumatology

Volumn 31, Issue 11, 2012, Pages 1567-1575

  Scrivo, Rossana ^a   Sauzullo, Ilaria ^b   Mengoni, Fabio ^b   Iaiani, Giancarlo ^b   Vestri, Anna Rita ^b   Priori, Roberta ^a   Di Filippo, Elisa ^b   Di Franco, Manuela ^a   Spinelli, Francesca Romana ^a   Vullo, Vincenzo ^b   Mastroianni, Claudio Maria ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti TNF; QuantiFERON TB gold in tube; Rheumatoid arthritis; Tuberculin skin test

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; FEMALE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL AGENTS; FEMALE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84872172803     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2049-6     Document Type: Article

References (44)

1. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K (2012) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 71(Suppl 2):i2-i45
2. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumor necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 3(3):148-155
3. Dixon WG, Hyrich KL,Watson KD, Lunt M, Galloway J, Ustianowski A, BSRBR Control Centre Consortium, Symmons DP; BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522-528
4. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies Group (2009) Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60(7):1884-1894
5. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8(10):601-611
6. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement (2000) Am J Respir Crit Care Med 161(4 Pt 2):S221-S247
7. Pai M, Menzies D (2007) The new IGRA and the old TST. Making good use of disagreement. Am J Respir Crit Care Med 175(6):529-531
8. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee; Centers for Disease Control and Prevention (CDC) (2010) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 59(RR-5):1-25
9. Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159(1):15-21
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315-324
11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Study Group CASPAR (2006) Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 54(8):2665-2673
12. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27(4):361-368
13. International Study Group for Behcet's Disease: Criteria for diagnosis of Behcet's disease (1990) Lancet 335(8697):1078-1080
14. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P (2006) Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 7:56
15. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367(9519):1328-1334
16. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A (2008) Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 27 (10):907-913
17. Matulis G, Juni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67 (1):84-90
18. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59(6):800-806
19. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M (2008) Comparison of an interferon gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35 (5):776-781
20. Sauzullo I, Mengoni F, Scrivo R, Valesini G, Potenza C, Skroza N, Marocco R, Lichtner M, Vullo V, Mastroianni CM (2010) Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumor necrosis factor-alpha treatment. Int J Tuberc Lung Dis 14 (7):834-840
21. Martin J,Walsh C, Gibbs A,McDonnell T, Fearon U, Keane J, Codd MB, Dodd J, Veale D, Fitzgerald O, Bresnihan B (2010) Comparison of interferon gamma release assays and conventional screening tests before tumour necrosis factor alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 69(1):181-185
22. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L (2005) Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 172(5):631-635
23. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185-1206
24. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF{alpha} inhibitors: the utility of IFN{gamma} assay. Ann Rheum Dis 71(2):231-237
25. Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, Sandstede J, Frosch M, Tony HP, Kneitz C (2010) Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 69(4):782-784
26. Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-Lassen I, Ravn P (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17(11):2340-2349
27. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ (2008) Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 35(7):1271-1276
28. Leyten EM, Arend SM, Prins C, Cobelens FG, Ottenhoff TH, van Dissel JT (2007) Discrepancy between mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 14 (7):880-885
29. Kwakernaak AJ, Houtman PM, Weel JF, Spoorenberg JP, Jansen TL (2011) A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor. Clin Rheumatol 30(4):505-510
30. Gomez-Reino JJ, Carmano L, Descalzo A, BIOBADASER GROUP (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756-761
31. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH (2009) Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during antitumor necrosis factor agent trial. J Rheumatol 36(10):2158-2163
32. Takahashi H, Shigehara K, Yamamoto M, Suzuki C, Naishiro Y, Tamura Y, Hirohashi Y, Satoh N, Shijubo N, Shinomura Y, Imai K (2007) Interferon γ assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 27(12):1143-1148
33. Garcovich S, Ruggeri A, D'Agostino M, Ardito F, De Simone C, Delogu G, Fadda G (2012) Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNFalpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol. doi: 10.1111/j.1468-3083. 2011.04220.x
34. Kim KH, Lee SW, Chung WT, Kim BG, Woo KS, Han JY, Kim JM (2011) Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 31(4):271-278
35. Ringrose JS, Sanche SE, Taylor-Gjevre RM (2011) Detecting latent tuberculosis infection during antitumor necrosis factor therapy. Clin Exp Rheumatol 29(5):790-794
36. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D (2004) Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38(5):754-756
37. Katiyar SK, Sampath A, Bihari S, Mamtani M, Kulkarni H (2008) Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis 12(10):1146-1152
38. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, Marocco R, Del Borgo C, Soscia F, Vullo V, Mastroianni CM (2009) In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One 4: e5187
39. Veerapathran A, Joshi R, Goswami K, Dogra S, Moodie EE, Reddy MV, Kalantri S, Schwartzman K, Behr MA, Menzies D, Pai M (2008) T-cell assays for tuberculosis infection: deriving cutoffs for conversions using reproducibility data. PLoS One 3:e1850
40. Herrera V, Yeh E, Murphy K, Parsonnet J, Banaei N (2010) Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay. J Clin Microbiol 48 (8):2672-2676
41. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D, RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group, (2006) Inhibition of anti-tuberculosis Tlymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114
42. Leyten EM, Prins C, Bossink AW, Thijsen S, Ottenhoff TH, van Dissel JT, Arend SM (2007) Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay. Eur Respir J 29(6):1212-1216
43. Richeldi L, Bergamini BM, Vaienti F (2008) Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts. Eur Respir J 32(2):524-525
44. Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, Ajassa C, Vullo V, Mastroianni CM (2011) Influence of previous tuberculin skin test on serial IFN-γ release assays. Tuberculosis 91 (4):322-326